These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31106898)

  • 21. Hydroxycarbamide: clinical aspects.
    Ware RE
    C R Biol; 2013 Mar; 336(3):177-82. PubMed ID: 23643402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
    Brandow AM; Panepinto JA
    Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea: Analytical techniques and quantitative analysis.
    Marahatta A; Ware RE
    Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
    F1000Res; 2018; 7():. PubMed ID: 30228870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
    Paule I; Sassi H; Habibi A; Pham KP; Bachir D; Galactéros F; Girard P; Hulin A; Tod M
    Orphanet J Rare Dis; 2011 May; 6():30. PubMed ID: 21619673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea.
    Nottage KA; Ware RE; Winter B; Smeltzer M; Wang WC; Hankins JS; Dertinger SD; Shulkin B; Aygun B
    Eur J Haematol; 2014 Nov; 93(5):377-83. PubMed ID: 24796940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 30. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.
    Sheehan VA; Crosby JR; Sabo A; Mortier NA; Howard TA; Muzny DM; Dugan-Perez S; Aygun B; Nottage KA; Boerwinkle E; Gibbs RA; Ware RE; Flanagan JM
    PLoS One; 2014; 9(10):e110740. PubMed ID: 25360671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
    Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
    J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
    Quarmyne MO; Dong W; Theodore R; Anand S; Barry V; Adisa O; Buchanan ID; Bost J; Brown RC; Joiner CH; Lane PA
    Am J Hematol; 2017 Jan; 92(1):77-81. PubMed ID: 27761932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
    Power-Hays A; Tomlinson GA; Tshilolo L; Santos B; Williams TN; Olupot-Olupot P; Smart LR; Aygun B; Lane A; Stuber SE; Latham T; Ware RE
    Am J Hematol; 2024 Apr; 99(4):625-632. PubMed ID: 38332651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.
    Creary SE; Beeman C; Stanek J; King K; McGann PT; O'Brien SH; Liem RI; Holl J; Badawy SM
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29607. PubMed ID: 35373884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
    Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
    Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
    Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
    Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.